Core Viewpoint - Novo Nordisk's recent financial report indicates strong sales growth driven by its obesity care business, despite facing challenges in the U.S. market due to generic drug competition and slower market expansion [1][2][10]. Financial Performance - For the first half of 2025, Novo Nordisk reported sales of 154.9 billion Danish Krone (approximately 22.3 billion USD), a year-on-year increase of 18% at constant exchange rates [1]. - Operating profit reached 72.2 billion Krone (approximately 10.4 billion USD), reflecting a 29% year-on-year growth [1]. - The obesity care segment saw a remarkable sales increase of 56%, contributing significantly to overall growth [1]. Product Performance - The diabetes and obesity care division generated sales of 145.4 billion Krone (approximately 21.5 billion USD), with obesity drug sales rising 58% to 38.8 billion Krone (approximately 5.7 billion USD) [1]. - Specific product sales included Ozempic at 64.5 billion Krone (approximately 9.6 billion USD) with a 15% increase, Rybelsus at 11.3 billion Krone (approximately 1.7 billion USD) with a 5% increase, and Wegovy at 36.9 billion Krone (approximately 5.4 billion USD) with a 78% increase [1]. Market Challenges - In Q2 2025, operating profit was 33.4 billion Krone (approximately 4.8 billion USD), falling short of market expectations due to a slowdown in the U.S. market [2]. - The company has lowered its revenue and operating profit forecasts for 2025, citing decreased growth expectations for Wegovy and Ozempic in the U.S. market [10]. Industry Trends - The GLP-1 drug market is projected to exceed 17 billion USD by 2031, with a compound annual growth rate of 15.6% from 2021 to 2031 [5]. - There is a significant unmet need in obesity treatment, with only 27% of eligible patients currently receiving GLP-1 therapy in major markets [5]. Strategic Initiatives - Novo Nordisk is focusing on expanding its production capacity and adapting its product offerings to meet market demands [15][16]. - The company is investing in new facilities and partnerships to enhance its operational capabilities and direct patient outreach [11][16]. - The appointment of a new CEO aims to drive growth and navigate the competitive landscape in the metabolic disease treatment sector [14][17].

1. 8月6日(周三)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.35%，标普500指数期货涨0.24%，纳指期货涨 0.23%。 2. 截至发稿，德国DAX指数涨0.02%，英国富时100指数涨0.20%，法国CAC40指数涨0.28%，欧洲斯托克50指数涨0.22%。 3. 截至发稿，WTI原油涨1.63%，报66.22美元/桶。布伦特原油涨1.52%，报68.67美元/桶。 | 瑞 伦敦布伦特原油 | 2025年10月 | 68.67 | 68.81 | 67.65 | +1.03 | +1.52% | | --- | --- | --- | --- | --- | --- | --- | | 雪 WTI原油 | 2025年9月 | 66.22 | 66.34 | 65.12 | +1.06 | +1.63% | 市场消息 降息预期凌乱，华尔街投行"吵"起来。美国"非农"数据暴雷令美联储降息预期飙升，但本周华尔街知名投行对降息分歧却在加 大。高盛、花旗均认为，9月或激进降息，摩根大通甚至认为今年可能降息125个基点。然而，美银认为今年美联储或按兵不 动，巴克莱和汇丰同样态度谨慎。未来几个月将 ...

盘前市场动向 1. 8月6日(周三)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.35%，标普500指数期货涨0.24%，纳指期货涨 0.23%。 | = US 30 | 44,267.00 | 44,364.00 | 44,074.50 | +155.30 | +0.35% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,314.10 | 6,332.90 | 6,287.60 | +14.90 | +0.24% | | 트 US Tech 100 | 23,072.30 | 23,118.10 | 22,937.50 | +53.70 | +0.23% | 2. 截至发稿，德国DAX指数涨0.02%，英国富时100指数涨0.20%，法国CAC40指数涨0.28%，欧洲斯托克50指数涨0.22%。 | 德国DAX30 | 23,862.00 | 23,998.59 | 23,806.00 | +4.81 | +0.02% | | --- | --- | --- | --- | --- | --- | | 器 英国富时100 | 9,16 ...

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [8][42] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [42] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [46] Business Line Data and Key Metrics Changes - U.S. Operations sales grew by 17%, while international operations grew by 19% [12] - GLP-1 diabetes care sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - The company serves nearly 46 million patients with diabetes and obesity treatments, an increase of over 3.5 million patients compared to the first half of 2024 [10] - In international operations, GLP-1 diabetes sales increased by 10%, while obesity care sales grew by 125% [22] - The company holds a 71% market share in the GLP-1 segment in international operations [24] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [30] - A focus on innovation and operational efficiency is emphasized, with plans to enhance commercial execution [59] - The company is investing in a broad portfolio of treatments to address diverse patient segments in the obesity market [30] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [9][49] - The company remains confident in its ability to treat more patients with chronic diseases despite the adjustments in expectations [54] - The management highlighted the importance of addressing the unmet needs in diabetes and obesity globally [28] Other Important Information - The company has initiated a Phase III clinical development program for amicretin, targeting obesity and associated comorbidities [35] - The company plans to launch oral semaglutide for obesity in the U.S. next year without supply restrictions [103] - An interim dividend of DKK 3.75 per share has been announced, reflecting a 7% increase compared to the previous year [48] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the conversion from the CVS formulary and is seeing results in line with expectations [66] Question: Has Novo initiated any litigation regarding compounding practices? - The company is prioritizing patient safety and is in dialogue with the FDA regarding illegal compounding practices, but specifics on litigation were not disclosed [68] Question: What is the outlook for growth in China? - Management clarified that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth potential [75] Question: What changes in R&D focus can be expected? - The company will focus more on diabetes and obesity, reallocating resources to enhance growth in these core areas [82] Question: How is the company positioned for the launch of oral semaglutide? - The company is well-positioned for the launch of oral semaglutide for obesity next year, with no supply restrictions anticipated [103] Question: What are the pricing strategies for Wegovy and Ozempic? - Management is focused on volume growth but is also considering pricing strategies for the second half of the year [116]

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [7][44] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [44] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [48] Business Line Data and Key Metrics Changes - U.S. Operations grew by 17%, while international operations grew by 19% in total sales [12] - GLP-1 diabetes sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - Sales in international operations grew by 19%, with GLP-1 diabetes sales increasing by 10% [23] - Obesity care sales in international operations grew by 125%, with Wegovy sales alone reaching DKK 12.2 billion, growing at 335% [24] - The company remains the market leader in international operations with a 71% market share in GLP-1 products [25] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [31] - A focus on innovation and addressing diverse patient segments through a broad portfolio of treatments is emphasized [31] - The company plans to continue rolling out Wegovy in more countries and invest in commercial execution [26][31] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [7][51] - The company is confident in its ability to treat more people living with chronic diseases despite the adjustments in expectations [56] - The management highlighted the importance of operational efficiency and commercial execution moving forward [60] Other Important Information - The company announced an interim dividend of DKK 3.75 per share, a 7% increase compared to August 2024 [49] - Capital expenditure for 2025 is expected to be around DKK 65 billion, reflecting expansion of the global supply chain [54] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the CVS formulary conversion and sees it aligning with expectations, but specific numbers on lives affected were not disclosed [67][68] Question: Has Novo initiated any litigation regarding compounding practices? - Management confirmed that protecting patient safety is a priority and that legal actions are being considered, with ongoing dialogue with the FDA [68][69] Question: What is the outlook for growth in China? - Management stated that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth due to unmet needs [75][78] Question: What changes in R&D focus can be expected? - Management indicated a continued focus on diabetes and obesity, emphasizing execution and reallocating resources to areas of growth [81][83] Question: What is the rationale behind discontinuing development of Sulfiram for NASH? - The decision was based on a lack of differentiation from semaglutide in trials, which demonstrated strong efficacy [112][113]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 6, 2025 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé DK-2880 Bagsværd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F x Form 40-F o Indicate by check ma ...

⑤ 【马斯克：特斯拉正在训练新的FSD模型】8月6日，马斯克在X上发文称，特斯拉正在训练新的FSD 模型，新模型的参数规模约为当前版本的十倍，如果一切顺利则可能会在下个月底准备好面向公众发 布。 ⑥ 【大幅下调营收指引，超微电脑盘前跌超16%】超微电脑盘前跌超16%。消息面上，超微电脑公布的 第四财季报告显示，公司预计下季度营收在60亿~70亿美元之间，调整后每股收益在0.40~0.52美元之 间。2026财年营收预期从此前的400亿美元下调至330亿美元，降幅达17.5%。 ① 【三大期指齐涨】截至发稿，道指期货涨0.29%、标普500指数期货涨0.23%、纳指期货涨0.06%。 ② 【中概股盘前涨跌不一】中概股盘前涨跌不一，阿里巴巴涨1.53%，拼多多涨1.07%，京东跌0.03%， 百度涨0.87%，理想汽车跌3.09%。 ③ 【即将公布Q2财报，优步盘前涨2.3%】优步盘前涨2.3%。消息面上，优步计划在周三市场开盘前公 布第二季度业绩。 ④ 【AMD二季度"增收不增利"，盘前跌超6%】美芯片巨头AMD盘前跌超6%。消息面上，公司最新公 布的财报显示，其二季度的营收超出预期，不过，二季度营业利润率仅为 ...

Financial Performance & Strategic Aspirations - Novo Nordisk achieved sales growth of 18% (CER) in the first six months of 2025, with operating profit growth of 29% (CER)[11] - Obesity care sales reached DKK 38.8 billion, a 58% increase at CER, highlighting the strong performance in this therapeutic area[11] - Rare disease sales increased by 15% at CER, reaching DKK 9.5 billion[11] - The company returned DKK 36.5 billion to shareholders, demonstrating a commitment to attractive capital allocation[11] Market Dynamics & Key Products - In the US, the branded anti-obesity medication market experienced growth exceeding 160%[28] - International Operations saw sales growth of 19%, driven by GLP-1 Diabetes and Obesity care[33] - Total GLP-1 class market share in International Operations reached 71%[36] - Global diabetes and obesity unmet need is significant, with less than 1% of people with obesity globally treated with branded AOMs[44] Research & Development Highlights - Amycretin is advancing to phase 3 development based on successful phase 1b/2a trial results, showing significant body weight loss[49, 53] - Semaglutide 2.4 mg demonstrated a 20% reduction in MACE in the SELECT trial for people with overweight or obesity and established CVD[249]

Listen below or on the go on Apple Podcasts and Spotify Novo Nordisk (NVO) plans cost cuts amid slower Wegovy growth outlook. (00:22) Disney’s (DIS) ESPN to acquire NFL media assets. (01:35) OpenAI reportedly exploring share sale at $500B valuation. (03:14) This is an abridged transcript. Novo Nordisk (NVO) is cutting costs. The Danish drugmaker says it is facing increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its treatmen ...

8月6日的最新财报显示，在2025年1月至6月期间，公司实现销售额1549亿丹麦克朗（约合223亿美 元），按固定汇率计算同比增长18%；营业利润达到722亿克朗（约合104亿美元），同比增长29%。这 一增长主要得益于肥胖症护理业务的显著表现，该领域销售额猛增56%（按丹麦克朗计算）。 拆分具体业务板块来看，糖尿病和肥胖护理部门销售额达到1454亿克朗，增长16%（215.14亿美元）， 同比增长18%。其中，肥胖症药物销售额同比增长58%至387.96亿丹麦克朗（57.40亿美元）。 值得一提的是，降糖用司美格鲁肽注射液Ozempic上半年销售645.20亿丹麦克朗（96.46亿美元），同比 增长15%；口服司美格鲁肽片Rybelsus销售113.48亿丹麦克朗（16.79亿美元），同比增长5%；减肥用司 美格鲁肽注射液Wegovy创收368.88亿丹麦克朗（54.58亿美元），同比增长78%。 不过，单独观察第二季度表现，诺和诺德的季度营业利润低于市场预期。第二季度，公司营业利润为 334亿克朗（约合48亿美元），此前行业机构预期为345亿克朗。这一差距主要源于美国市场增长放缓。 21世纪经济报道记者季 ...